Pathway of Low Anterior Resection Syndrome Relief After Surgery: a Feasibility Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

187 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-05-23

Study Completion Date

2023-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Currently, no standard exists for the treatment and management of Low Anterior Resection Syndrome (LARS)- a common disorder that affects patients who have had part of their bowel removed due to colorectal cancer. Decisions about which treatment patients receive is at the discretion of local clinicians, leading to a variation in both clinical practice and the outcomes of these patients. As a result, there is a need for research to assess what treatments are most effective in treating or managing LARS to establish a consensus and develop a treatment pathway in the UK. This study aims to assess the feasibility of undertaking such a trial utilising a novel 'trial within cohorts (TWiCs)' study design, with a view to informing the design of a full-scale trial.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Transanal Irrigation - Best Treatment Possibility for Low Anterior Resection Syndrome? Multicenter, Randomized Clinical Trial

NCT05920681

Low Anterior Resection Syndrome

RECRUITING NA

Transanal Irrigation to Prevent Major Low Anterior Resection Syndrome

NCT04758195

Low Anterior Resection Syndrome

UNKNOWN NA

Effect of Treatment of Low Anterior Resection Syndrome After Rectal Cancer Surgery

NCT03215017

Low Anterior Resection Syndrome

COMPLETED NA

Treatment of "Low Anterior Resection Syndrome" by Percutaneous Nerve Evaluation and Transanal Irrigation

NCT01313026

Rectal Cancer

TERMINATED NA

Impact of a Patient-Centered Program for Low Anterior Resection Syndrome a Multicenter Randomized Controlled Trial

NCT03828318

Rectal Cancer Surgery Patient Activation +2 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Rectal cancer (cancer of the lower part of the bowel) is one of the most prevalent forms of cancer, and affects approximately 14,000 people each year in the UK. The treatment for the majority of these patients is surgical removal of the affected part of the bowel, following which the bowel is joined back together. Some patients may also require chemotherapy and radiotherapy. One consequence of the treatment of bowel cancer is a severe form of bowel dysfunction called major Low Anterior Resection Syndrome (LARS).

LARS is a constellation of symptoms including incontinence to stool, urgency and frequency of bowel movements and incomplete evacuation; it is diagnosed using the LARS scoring tool. Major LARS can have a huge impact on the persons quality of life resulting in social isolation. Currently there are no guidelines for the management of LARS. The aim of the POLARiS study is to investigate three different treatments for major LARS; optimised conservative management, a combination of diet, medication, bowel retraining and pelvic floor exercises; transanal irrigation, washing out the back passage of stool with warmed water; and sacral nerve stimulation where an electrical impulse delivered to the sacral nerve to help with bowel function. This feasibility study aims to test the study design ahead of a larger fully powered randomised control trial. The study will firstly recruit any consenting adult who has had surgery for rectal cancer (called an anterior resection) and who does not have a stoma, into a cohort and then follow up those patients every 3 months with bowel function and quality of life assessments. Any patient found to have major LARS (LARS score over 30) will be invited into the randomised control trial where the above three treatments will be tested.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Low Anterior Resection Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Trials within Cohorts

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort

Patients who have undergone colonic resection for colorectal cancer in the last 10 years. Patient reported outcome measures collected at 3-monthly intervals.

Group Type NO_INTERVENTION

No interventions assigned to this group

Optimised Conservative Management

Cohort participants who are identified as having 'major LARS' at any point are treated with Optimised Conservative Managements, consisting of medication, dietary advice, lifestyle advice and physiotherapy.

Group Type ACTIVE_COMPARATOR

Optimised Conservative Management

Intervention Type OTHER

Optimised conservative management will include up-to 30 patients with major LARS. They will be provided with a resource booklet which includes dietary and lifestyle advice as well as exercises that can be undertaken independently.

Trans-Anal Irrigation

Cohort participants who are identified as having 'major LARS' at any point are treated with Trans-anal irrigation, in additional to receiving optimised conservative management. Transanal irrigation system will be decided upon with the participant and procured locally.

Group Type ACTIVE_COMPARATOR

Trans-Anal Irrigation

Intervention Type DEVICE

Trans-Anal irrigation group will include up-to 20 patients with major LARS. Specific system will be agreed with the patient, depending on eligibility and preference.

Optimised Conservative Management

Intervention Type OTHER

Optimised conservative management will include up-to 30 patients with major LARS. They will be provided with a resource booklet which includes dietary and lifestyle advice as well as exercises that can be undertaken independently.

Sacral NeuroModulation

Cohort participants who are identified as having 'major LARS' at any point are treated with Sacral Neuromodulation system, in addition to receiving optimised conservative management. Medtronic Interstim system will be used.

Group Type ACTIVE_COMPARATOR

Sacral NeuroModulation

Intervention Type DEVICE

Sacral Neuromodulation group will include up-to 20 patients with major LARS. Medtronic Interstim system will be used, including 2 week trial device.

Optimised Conservative Management

Intervention Type OTHER

Optimised conservative management will include up-to 30 patients with major LARS. They will be provided with a resource booklet which includes dietary and lifestyle advice as well as exercises that can be undertaken independently.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sacral NeuroModulation

Sacral Neuromodulation group will include up-to 20 patients with major LARS. Medtronic Interstim system will be used, including 2 week trial device.

Intervention Type DEVICE

Trans-Anal Irrigation

Trans-Anal irrigation group will include up-to 20 patients with major LARS. Specific system will be agreed with the patient, depending on eligibility and preference.

Intervention Type DEVICE

Optimised Conservative Management

Optimised conservative management will include up-to 30 patients with major LARS. They will be provided with a resource booklet which includes dietary and lifestyle advice as well as exercises that can be undertaken independently.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* For cohort:

* Diagnosis of rectal or sigmoid cancer
* Low or high anterior resection (colorectal resection with anastomosis to the rectum)
* Functioning anastomosis
* Aged 18 years and older
* Primary surgery/reversal of ileostomy less than 10 years before recruitment
* Reversal of ileostomy at least 12 weeks prior to recruitment with at least a further 12 weeks of standard care to manage symptoms following reversal
* Willing and able to provide valid informed consent
* For randomisation:

* Recruited to cohort study
* Willing and able to provide valid informed consent for randomisation
* Major LARS symptoms (Defined as score of 30+ on LARS scoring tool)
* Previous unsuccessful conservative treatment determined by treating clinician and patient

Exclusion Criteria

* For cohort

\- Inability to understand and complete study questionnaires independently. (Due to cognitive or intellectual impairment, Due to insufficient English language skills)
* For randomised control trial

* Pregnancy
* No previous conservative treatment plan for the management of LARS
* Does not meet any treatment-specific criteria
* For TAI randomisation:

* Unable to perform TAI
* History of anastomotic leak with evidence of ongoing leak/sinus
* Previous use of TAI for LARS
* Site unable to offer TAI as a treatment
* Any other contraindications advised by the care team, product manufacturer or distributor
* For SNM randomisation:

* \<12months since primary cancer surgery
* Palliative disease
* Site unable to offer SNM as a treatment
* Previous SNM
* Specific contraindications to implantation
* Any other contraindications advised by the care team, product manufacturer or distributor.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No